Home
Storia in 1 fonti
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study - Forte Bi
Forte Biosciences reported positive Phase 1b vitiligo data, with FB102 showing significant facial repigmentation and favorable safety.
Raccontata da
benzinga.com
Timeline cronologica
- ·
Teva Reports Early Skin Repigmentation Data, Preps For Next Trial - Teva Pharmaceutical Indus (NYSE:TEVA)
Teva will advance TEV-'408 into a Phase 2b vitiligo study after Phase 1b data showed skin pigmentation improvements and favorable safety.
- ·
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study - Forte Bi
Forte Biosciences reported positive Phase 1b vitiligo data, with FB102 showing significant facial repigmentation and favorable safety.